Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Christine Fisher

Concepts (257)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Uterine Cervical Neoplasms
15
2025
268
4.190
 Why?
Brachytherapy
13
2023
133
3.830
 Why?
Endometrial Neoplasms
10
2025
205
1.900
 Why?
Uterine Neoplasms
6
2025
98
1.660
 Why?
Radiotherapy Planning, Computer-Assisted
7
2024
150
1.630
 Why?
Breast Neoplasms
21
2026
2420
1.620
 Why?
Hysterectomy
5
2019
138
1.570
 Why?
Radiosurgery
5
2025
400
1.430
 Why?
Carcinosarcoma
3
2023
23
1.270
 Why?
Neoplasm Recurrence, Local
12
2026
1166
0.970
 Why?
Neoplasm Staging
20
2026
1492
0.950
 Why?
Genital Neoplasms, Female
4
2024
100
0.940
 Why?
Radiation Oncology
5
2022
83
0.930
 Why?
Databases, Factual
5
2021
1504
0.910
 Why?
Radiotherapy, Intensity-Modulated
2
2024
143
0.810
 Why?
Carcinoma, Intraductal, Noninfiltrating
3
2017
61
0.730
 Why?
Chemoradiotherapy
4
2019
239
0.710
 Why?
Radiotherapy, Adjuvant
6
2019
222
0.640
 Why?
Healthcare Disparities
2
2018
740
0.620
 Why?
Medical Oncology
7
2026
344
0.590
 Why?
Simulation Training
1
2021
136
0.590
 Why?
Female
61
2026
80076
0.580
 Why?
Ovarian Neoplasms
1
2025
599
0.580
 Why?
Margins of Excision
1
2019
54
0.560
 Why?
Aquaporin 4
1
2019
102
0.550
 Why?
Necrosis
1
2019
245
0.540
 Why?
Insurance, Health
2
2018
321
0.530
 Why?
Aged
27
2026
26514
0.500
 Why?
Antineoplastic Agents, Immunological
1
2019
200
0.480
 Why?
Middle Aged
31
2026
36821
0.470
 Why?
Carcinoma, Neuroendocrine
1
2016
38
0.470
 Why?
Insurance Coverage
1
2018
248
0.470
 Why?
Standard of Care
1
2016
81
0.460
 Why?
Humans
68
2026
147293
0.460
 Why?
Perioperative Care
1
2018
231
0.450
 Why?
SEER Program
6
2021
232
0.440
 Why?
Antineoplastic Combined Chemotherapy Protocols
6
2023
2001
0.440
 Why?
Mastectomy
4
2026
188
0.430
 Why?
Adenocarcinoma
4
2024
928
0.420
 Why?
Health Plan Implementation
1
2015
142
0.420
 Why?
Medical Errors
1
2015
119
0.410
 Why?
Survival Rate
7
2019
2110
0.410
 Why?
Carcinoma, Ductal, Breast
1
2014
91
0.400
 Why?
Radiotherapy Dosage
5
2023
289
0.400
 Why?
Neoplasms
3
2022
2946
0.390
 Why?
Quality Assurance, Health Care
1
2015
343
0.390
 Why?
Tumor Suppressor Protein p53
3
2023
536
0.380
 Why?
Gene Expression Regulation, Neoplastic
1
2019
1457
0.370
 Why?
Carcinoma
1
2014
231
0.370
 Why?
Pelvis
1
2013
129
0.360
 Why?
Combined Modality Therapy
6
2020
1281
0.350
 Why?
Prostatectomy
1
2012
94
0.350
 Why?
Aged, 80 and over
13
2025
8430
0.350
 Why?
Practice Patterns, Physicians'
2
2018
1379
0.340
 Why?
Adult
23
2026
41405
0.340
 Why?
Vulvar Neoplasms
2
2024
13
0.330
 Why?
Internship and Residency
1
2021
1279
0.330
 Why?
Carcinoma, Endometrioid
2
2023
49
0.320
 Why?
Mastectomy, Segmental
4
2020
107
0.310
 Why?
Mutation
3
2023
4130
0.300
 Why?
United States
13
2022
16313
0.280
 Why?
Lymphatic Metastasis
3
2021
338
0.280
 Why?
Re-Irradiation
2
2020
10
0.280
 Why?
Cancer Pain
2
2018
41
0.250
 Why?
Prostatic Neoplasms
2
2012
986
0.250
 Why?
Vaginal Neoplasms
1
2026
20
0.240
 Why?
Sarcoma
2
2021
210
0.230
 Why?
Treatment Outcome
9
2023
11947
0.230
 Why?
Analgesics, Opioid
3
2021
1167
0.230
 Why?
Retrospective Studies
14
2024
17560
0.220
 Why?
Chemotherapy, Adjuvant
4
2021
429
0.220
 Why?
Regression Analysis
2
2019
1003
0.210
 Why?
Neoadjuvant Therapy
2
2018
474
0.210
 Why?
Stakeholder Participation
1
2025
89
0.200
 Why?
Follow-Up Studies
4
2018
5476
0.200
 Why?
Papillomavirus Infections
2
2019
345
0.200
 Why?
Young Adult
8
2021
14437
0.190
 Why?
Prognosis
6
2023
4383
0.190
 Why?
Quality of Life
2
2026
3246
0.190
 Why?
Adenocarcinoma, Clear Cell
1
2023
14
0.190
 Why?
Carcinoma, Renal Cell
2
2015
233
0.190
 Why?
Positron-Emission Tomography
1
2024
344
0.190
 Why?
Kaplan-Meier Estimate
4
2021
975
0.180
 Why?
Consensus
1
2024
476
0.180
 Why?
Patient Participation
1
2026
449
0.180
 Why?
Tertiary Care Centers
1
2023
196
0.180
 Why?
Hodgkin Disease
2
2016
173
0.180
 Why?
Hydrocephalus
1
2023
114
0.180
 Why?
Colonic Neoplasms
1
2024
258
0.170
 Why?
Decision Support Techniques
1
2026
480
0.170
 Why?
Brain Neoplasms
2
2023
1338
0.170
 Why?
Mass Spectrometry
1
2025
728
0.170
 Why?
beta Catenin
2
2023
254
0.170
 Why?
Kidney Neoplasms
2
2015
421
0.160
 Why?
Carcinoma, Squamous Cell
2
2017
648
0.160
 Why?
Benchmarking
1
2021
194
0.160
 Why?
Cancer Care Facilities
1
2020
48
0.160
 Why?
High-Throughput Nucleotide Sequencing
1
2023
539
0.150
 Why?
Gestational Trophoblastic Disease
1
2019
6
0.150
 Why?
Veterans
2
2022
1675
0.150
 Why?
Benzodiazepines
1
2021
169
0.150
 Why?
Immunohistochemistry
1
2023
1730
0.150
 Why?
Magnetic Resonance Imaging
2
2024
3980
0.150
 Why?
Lymph Nodes
1
2021
514
0.140
 Why?
Triple Negative Breast Neoplasms
1
2021
220
0.140
 Why?
Communication
1
2025
989
0.130
 Why?
Practice Guidelines as Topic
2
2017
1598
0.130
 Why?
Referral and Consultation
1
2024
886
0.130
 Why?
Relative Biological Effectiveness
1
2017
4
0.130
 Why?
Pain Management
2
2018
415
0.130
 Why?
Patient Acceptance of Health Care
1
2024
895
0.130
 Why?
Proportional Hazards Models
2
2018
1344
0.120
 Why?
Radiotherapy, Conformal
1
2017
75
0.120
 Why?
Adolescent
5
2019
22825
0.120
 Why?
Breast
1
2017
157
0.120
 Why?
Neoplasms, Radiation-Induced
1
2016
100
0.120
 Why?
Logistic Models
2
2018
2142
0.120
 Why?
Antineoplastic Agents
3
2017
2231
0.120
 Why?
Radiotherapy Setup Errors
1
2015
3
0.120
 Why?
Tomography, X-Ray Computed
2
2024
2791
0.120
 Why?
Radiation Injuries
1
2017
149
0.110
 Why?
Pancreatic Neoplasms
1
2024
947
0.110
 Why?
Machine Learning
1
2021
596
0.110
 Why?
Propensity Score
1
2018
379
0.110
 Why?
Neoplasms, Second Primary
1
2016
103
0.110
 Why?
Neoplasm Grading
4
2019
313
0.110
 Why?
Quality Control
1
2015
161
0.110
 Why?
Medically Uninsured
1
2015
133
0.110
 Why?
Risk Reduction Behavior
1
2016
221
0.110
 Why?
Radiation Tolerance
1
2015
103
0.110
 Why?
Physicians
1
2023
961
0.110
 Why?
Drug Administration Schedule
1
2016
789
0.100
 Why?
Curriculum
1
2021
1082
0.100
 Why?
Checklist
1
2015
111
0.100
 Why?
Soft Tissue Neoplasms
1
2015
133
0.100
 Why?
Cancer Vaccines
2
2005
164
0.100
 Why?
Risk Factors
6
2020
11017
0.100
 Why?
Breast Neoplasms, Male
1
2013
29
0.100
 Why?
Case-Control Studies
2
2019
3660
0.100
 Why?
Skin Neoplasms
2
2024
865
0.100
 Why?
Internet
1
2018
696
0.100
 Why?
Tumor Burden
1
2014
327
0.100
 Why?
Clinical Competence
1
2021
1260
0.100
 Why?
Gene Expression Profiling
2
2017
1794
0.090
 Why?
Guideline Adherence
1
2017
590
0.090
 Why?
Neoplasm Invasiveness
1
2014
512
0.090
 Why?
Socioeconomic Factors
1
2017
1342
0.090
 Why?
Bone Neoplasms
1
2015
272
0.090
 Why?
Randomized Controlled Trials as Topic
1
2019
1776
0.090
 Why?
Biomarkers, Tumor
4
2023
1339
0.090
 Why?
Patient Safety
1
2015
356
0.090
 Why?
Poly-ADP-Ribose Binding Proteins
2
2023
33
0.090
 Why?
DNA Polymerase II
2
2023
35
0.090
 Why?
Peptide Fragments
2
2005
698
0.090
 Why?
Texas
1
2012
278
0.080
 Why?
Medicaid
1
2015
475
0.080
 Why?
Male
12
2024
73950
0.080
 Why?
Disease Management
1
2014
654
0.080
 Why?
Age Factors
1
2017
3372
0.070
 Why?
Quality Indicators, Health Care
2
2022
337
0.070
 Why?
Lung Neoplasms
1
2023
2679
0.070
 Why?
Registries
1
2018
2434
0.070
 Why?
Cohort Studies
3
2021
6099
0.070
 Why?
Melanoma
1
2015
774
0.070
 Why?
Survival Analysis
1
2012
1386
0.070
 Why?
Liver Neoplasms
1
2015
787
0.070
 Why?
Risk Assessment
2
2020
3784
0.070
 Why?
Epidemics
2
2018
96
0.060
 Why?
Fertility Preservation
2
2019
57
0.060
 Why?
Opioid-Related Disorders
3
2021
617
0.060
 Why?
Gynecology
2
2018
184
0.060
 Why?
Prospective Studies
4
2023
8164
0.050
 Why?
Medicare
2
2021
915
0.050
 Why?
Prevalence
1
2012
2889
0.050
 Why?
Prostate-Specific Antigen
1
2005
162
0.050
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
1
2005
161
0.050
 Why?
Paget Disease, Extramammary
1
2024
4
0.050
 Why?
Radiotherapy
2
2015
210
0.050
 Why?
DNA Mismatch Repair
1
2023
54
0.050
 Why?
Information Seeking Behavior
1
2023
40
0.050
 Why?
Aromatase
1
2023
37
0.050
 Why?
Needles
1
2023
63
0.050
 Why?
Time Factors
4
2020
7173
0.040
 Why?
Surveys and Questionnaires
2
2026
6164
0.040
 Why?
Receptors, Estrogen
2
2016
406
0.040
 Why?
Focus Groups
1
2025
587
0.040
 Why?
Anthracyclines
1
2021
49
0.040
 Why?
Taxoids
1
2021
116
0.040
 Why?
Clinical Trials, Phase I as Topic
1
2020
50
0.040
 Why?
Hospitals, University
1
2021
176
0.040
 Why?
Precision Medicine
1
2025
464
0.040
 Why?
Trastuzumab
1
2021
119
0.040
 Why?
Estrogens
1
2023
368
0.040
 Why?
Quinolines
1
2021
192
0.040
 Why?
Radiometry
1
2019
56
0.040
 Why?
Microsatellite Instability
1
2019
57
0.040
 Why?
Chemoradiotherapy, Adjuvant
1
2019
44
0.040
 Why?
Papanicolaou Test
1
2019
35
0.040
 Why?
Organ Sparing Treatments
1
2019
37
0.040
 Why?
Cervix Uteri
1
2019
50
0.040
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2019
108
0.030
 Why?
Radiotherapy, Image-Guided
1
2018
40
0.030
 Why?
Guidelines as Topic
1
2020
268
0.030
 Why?
Papillomaviridae
1
2019
116
0.030
 Why?
India
1
2018
221
0.030
 Why?
Neoplasm Metastasis
1
2020
695
0.030
 Why?
PTEN Phosphohydrolase
1
2019
165
0.030
 Why?
Equipment Design
1
2019
527
0.030
 Why?
United States Department of Veterans Affairs
1
2022
793
0.030
 Why?
Organs at Risk
1
2017
37
0.030
 Why?
Vagina
1
2019
206
0.030
 Why?
Statistics, Nonparametric
1
2017
430
0.030
 Why?
Predictive Value of Tests
1
2021
2133
0.030
 Why?
Skin Ulcer
1
2015
15
0.030
 Why?
HLA-A2 Antigen
2
2005
36
0.030
 Why?
Thoracic Neoplasms
1
2015
40
0.030
 Why?
Abdominal Neoplasms
1
2015
48
0.030
 Why?
Antibodies, Monoclonal, Humanized
1
2021
1005
0.030
 Why?
Fibrosis
1
2017
568
0.030
 Why?
Societies, Medical
1
2019
914
0.030
 Why?
Odds Ratio
1
2017
1084
0.030
 Why?
Evidence-Based Medicine
1
2018
742
0.030
 Why?
Reoperation
1
2017
644
0.020
 Why?
Clinical Decision-Making
1
2017
367
0.020
 Why?
Disease Progression
2
2015
2890
0.020
 Why?
Biopsy
1
2017
1093
0.020
 Why?
Confidence Intervals
1
2013
330
0.020
 Why?
Age Distribution
1
2013
406
0.020
 Why?
Sex Distribution
1
2013
390
0.020
 Why?
Membrane Proteins
1
2019
1171
0.020
 Why?
Receptors, Progesterone
1
2013
244
0.020
 Why?
Skin
1
2017
759
0.020
 Why?
Comorbidity
1
2017
1672
0.020
 Why?
Clinical Trials as Topic
1
2017
1072
0.020
 Why?
Vinblastine
1
2011
75
0.020
 Why?
Dacarbazine
1
2011
101
0.020
 Why?
Analysis of Variance
1
2013
1302
0.020
 Why?
Remission Induction
1
2011
310
0.020
 Why?
Colorado
1
2020
4591
0.020
 Why?
Bleomycin
1
2011
256
0.020
 Why?
Mass Screening
1
2019
1375
0.020
 Why?
Doxorubicin
1
2011
411
0.020
 Why?
Algorithms
1
2017
1868
0.020
 Why?
Sex Factors
1
2013
2136
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2458
0.020
 Why?
Incidence
1
2013
2954
0.020
 Why?
Pregnancy
1
2019
7274
0.010
 Why?
Cytotoxicity Tests, Immunologic
1
2005
39
0.010
 Why?
Cytotoxicity, Immunologic
1
2005
224
0.010
 Why?
T-Lymphocytes, Cytotoxic
1
2005
179
0.010
 Why?
Immunoconjugates
1
2005
138
0.010
 Why?
Cross-Sectional Studies
1
2015
6011
0.010
 Why?
Leukocytes, Mononuclear
1
2005
590
0.010
 Why?
Interferon-gamma
1
2005
786
0.010
 Why?
CD8-Positive T-Lymphocytes
1
2005
932
0.010
 Why?
Cell Line, Tumor
1
2005
3565
0.010
 Why?
Child
1
2013
22979
0.010
 Why?
Fisher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (257) concept(s)
_
Co-Authors Expand Description
See all (48) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)